In a significant stride towards strengthening India\u2019s clinical research ecosystem, the Indian Council of Medical Research (ICMR) has formalized Memorandum of Agreements (MoAs) with multiple sponsors under its Network of Phase 1 Clinical Trials. The agreements mark a ground-breaking entry into First-in-Human Clinical Trials for four promising molecules. These include collaborative research over a small molecule for multiple myeloma with Aurigene Oncology Limited, partnering for Zika vaccine development with Indian Immunologicals Limited, coordinating seasonal Influenza virus vaccine trial with Mynvax Private Limited, and CAR-T cell therapy advancement study for a new indication of chronic lymphocytic leukemia with ImmunoACT. This initiative is a crucial step towards establishing India as a leader in the clinical development of pharmaceutical agents.<\/p>\n
Union Health and Family Welfare Minister, Shri J P Nadda, commended the strategic collaboration between ICMR and prominent industry and academic partners, emphasizing it as a key milestone in the pursuit of affordable and accessible cutting-edge treatments for all citizens. He noted that this initiative positions India to emerge as a global leader in healthcare innovation.<\/p>\n
Dr. Rajiv Bahl, Secretary, Department of Health Research & Director General, ICMR, emphasized the transformative potential of the project, stating, \u201cThis collaboration reflects our commitment to advancing clinical research in India through strategic public-private partnerships. Establishing Phase 1 clinical trial infrastructure is a key component in fostering the development of indigenous molecules and cutting-edge treatments. Our vision is to expand this network further, ensuring that India continues to lead in the development of innovative and affordable healthcare solutions.\u201d<\/p>\n
Dr. Bahl also highlighted the broader impact of ICMR\u2019s initiatives, such as the Network for Phase 1 Clinical Trials, INTENT Network, and MedTech Mitra, aligning with the government\u2019s vision of a \u201cViksit Bharat\u201d (Developed India). He cited ICMR\u2019s pivotal role in development of Covaxin in collaboration with Bharat Biotech as a testament to the organization\u2019s commitment to affordable and accessible healthcare for all.<\/p>\n
The ICMR Network for Phase 1 Clinical Trials comprises four strategically located institutions across India\u2014KEMH & GSMC, Mumbai; ACTREC, Navi Mumbai; SRM MCH&RC, Kattankulathur; and PGIMER, Chandigarh\u2014supported by a Central Coordinating Unit at ICMR Headquarters, New Delhi. This network is designed to build and enhance India\u2019s capacity to conduct early-phase clinical trials, supported by robust infrastructure and dedicated manpower at each trial site, ensuring smooth and effective operations.<\/p>\n
The signing of these agreements reinforces the strong partnerships ICMR has cultivated with key industry players. It underscores the institute\u2019s dedication to building a robust clinical trial ecosystem in India, fostering capacity to develop new drugs from early-phase trials through to marketing, thereby reducing dependency on international resources, and ultimately driving the mission of affordable, high-quality healthcare for all.<\/p>\n","protected":false},"excerpt":{"rendered":"
In a significant stride towards strengthening India\u2019s clinical research ecosystem, the Indian Council of Medical Research (ICMR) has formalized Memorandum of Agreements (MoAs) with multiple sponsors under its Network of Phase 1 Clinical Trials. The agreements mark a ground-breaking entry into First-in-Human Clinical Trials for four promising molecules. These include collaborative research over a small […]<\/p>\n","protected":false},"author":12,"featured_media":106422,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[52905],"tags":[],"class_list":["post-17782","post","type-post","status-publish","format-standard","has-post-thumbnail","category-national"],"_links":{"self":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/17782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=17782"}],"version-history":[{"count":0,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/17782\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media\/106422"}],"wp:attachment":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=17782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=17782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=17782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}